Pharmacologic class: Epidermal growth factor receptor (EGFR) inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D


Unclear. Drug inhibits intracellular phosphorylation of tyrosine kinase associated with EGFR, which is expressed on cell surface of both normal cells and cancer cells.


Tablets: 25 mg, 100 mg, 150 mg

Indications and dosages

Locally advanced or metastatic non-small-cell lung cancer after failure of at least one chemotherapy regimen; maintenance treatment in patients whose disease hasn't progressed after four cycles of platinumbased first-line chemotherapy

Adults: 150 mg P.O. at least 1 hour before or 2 hours after food ingestion, continued until disease progresses or unacceptable toxicity occurs

First-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer (given with gemcitabine)

Adults: 100 mg P.O. daily at least 1 hour before or 2 hours after food ingestion, continued until disease progresses or unacceptable toxicity occurs

Dosage adjustment

• Severe diarrhea

• Pretreatment with CYP3A4 inducers

• Concurrent use of potent CYP3A4 inhibitors (such as ketoconazole)

• Acute onset of new or progressing pulmonary symptoms

Off-label uses

• Colorectal and renal cell cancer

• Malignant glioma




Use cautiously in:

• hepatic impairment, diarrhea

• pulmonary symptoms, suspected interstitial lung disease (such as pneumonitis, interstitial pneumonia, obliterative bronchiolitis, pulmonary fibrosis, adult respiratory distress syndrome, or lung filtration)

• concomitant use of anti-angiogenic agents, corticosteroids, nonsteroidal anti-inflammatory drugs, or taxane-based chemotherapy; prior history of peptic ulceration or diverticular disease

• concurrent warfarin therapy

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


• Give at least 1 hour before or 2 hours after food ingestion.

Interrupt therapy if patient develops acute onset of new or progressing pulmonary symptoms pending diagnostic evaluation. If interstitial lung disease develops, discontinue drug and administer appropriate interventions.

Be aware that some cases of hepatorenal syndrome, acute renal failure, and renal insufficiency may be secondary to baseline hepatic impairment while others may be associated with severe dehydration. Interrupt therapy and take appropriate measures to intensively rehydrate patient, as needed.

Discontinue drug if total bilirubin level is above three times upper limit of normal (ULN) or transaminase levels are above five times ULN versus pretreatment values; signs and symptoms of GI perforation occur; severe bullous, blistering, or exfoliating conditions develop; or acute or worsening ocular disorders such as eye pain occur.

Adverse reactions

CNS: fatigue

EENT: conjunctivitis, keratoconjunctivitis sicca corneal perforation and ulceration

GI: nausea, vomiting, diarrhea, abdominal pain, anorexia, stomatitis GI perforation

GU: renal insufficiency, acute renal failure

Hepatic: hepatorenal syndrome, hepatic failure

Respiratory: dyspnea, cough, interstitial lung disease

Skin: rash, pruritus, dry skin, Stevens-Johnson syndrome, toxic epidermal necrolysis-like reactions

Other: infection


Drug-drug. CYP3A4 inhibitors (such as clarithromycin, indinavir, itraconazole, ketoconazole, ritonavir, saquinavir, telithromycin): increased erlotinib blood level

CYP3A4 inducers (such as carbamazepine, phenobarbital, phenytoin, rifampin): decreased erlotinib blood level

Warfarin, other coumarin anticoagulants: elevated INR, increased bleeding risk

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase, bilirubin: increased

International Normalized Ratio: increased

Liver function tests: abnormal

Drug-food. Any food: increased erlotinib bioavailability

Drug-herb. Coenzyme Q10: decreased chemotherapy efficacy

St. John's wort: decreased erlotinib blood level

Drug-behaviors. Smoking: decreased erlotinib plasma concentration

Patient monitoring

Perform periodic serum electrolyte measurements and renal and liver function testing.

• Advise patient not to smoke while taking drug.

• Monitor INR and prothrombin time regularly in patients receiving warfarin, other coumarin anticoagulants, or nonsteroidal anti-inflammatory drugs.

Monitor for signs and symptoms of respiratory disorders and GI perforation.

Patient teaching

Advise patient to seek immediate medical attention for severe or persistent diarrhea, nausea, vomiting, anorexia, severe rash, eye pain, eye irritation, or onset or worsening of unexplained shortness of breath or cough.

• Advise patient not to smoke while taking drug.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and herbs mentioned above.


(er-lo-ti-nib) ,


(trade name)


Therapeutic: antineoplastics
Pharmacologic: enzyme inhibitors
Pregnancy Category: D


genetic implication First-line therapy of metastatic non–small-cell lung cancer that has epidermal growth factor exon 19 deletions or exon 21 substitution mutations.Maintenance treatment of locally advanced/metastatic non–small-cell lung cancer when disease has not progressed after four cycles of platinum-based first-line chemotherapy.Locally advanced/metastatic non–small-cell lung cancer that has not responded to ≥1 previous chemotherapy regimenFirst-line therapy for locally advanced, surgically unresectable, or metastatic pancreatic cancer (with gemcitabine).


genetic implication Inhibits the enzyme tyrosine kinase, which is associated with human epidermal growth factor receptor (EGFR); blocks growth stimulation signals in cancer cells.

Therapeutic effects

Decreased spread of lung or pancreatic cancer with increased survival.


Absorption: 60% absorbed; bioavailability ↑ to 100% with food.
Distribution: Unknown.
Protein Binding: 93% protein bound.
Metabolism and Excretion: Mostly metabolized by the liver (CYP3A4 enzyme system).
Half-life: 36 hr.

Time/action profile (blood levels)

Oralunknown4 hr24 hr


Contraindicated in: Obstetric / Lactation: Pregnancy or lactation.
Use Cautiously in: Hepatic impairment;Previous chemotherapy/radiation, pre-existing lung disease, metastatic lung disease (may ↑ risk of interstitial lung disease);Patients with child-bearing potential; Pediatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • cerebrovascular accident (pancreatic cancer patients) (life-threatening)
  • fatigue


  • myocardial infarction/ischemia (pancreatic cancer patients) (life-threatening)

Ear, Eye, Nose, Throat

  • conjunctivitis
  • corneal perforation
  • corneal ulceration


  • interstitial lung disease (life-threatening)
  • dyspnea (most frequent)
  • cough


  • hepatotoxicity
  • gi perforation (life-threatening)
  • diarrhea (most frequent)
  • abdominal pain
  • anorexia
  • nausea
  • stomatitis
  • vomiting
  • ↑ liver enzymes


  • bullous and exfoliative skin disorders (life-threatening)
  • rash (most frequent)
  • dry skin
  • pruritus


  • renal failure (life-threatening)


  • microangiopathic hemolytic anemia with thrombocytopenia (pancreatic cancer patients)


Drug-Drug interaction

Strong inhibitors of CYP3A4, including atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, or voriconazole ↑ levels and the risk of toxicity; consider dose reduction.Strong inducers of CYP3A4, including rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, or phenobarbital ↓ levels and may ↓ response; alternative therapy or ↑ dose should be considered.Ciprofloxacin may ↑ levels and the risk of toxicity.Smoking may ↓ levels and may ↓ response; may consider ↑ dose if smoking continues.May ↓ midazolam levels.May ↑ risk of bleeding with warfarin.↓ levels with proton pump inhibitors and H2 blockers ; avoid concurrent use.St. John's wort may ↓ levels and may ↓ response; alternative therapy or ↑ dose should be considered.


Oral (Adults) Non–small-cell lung cancer–150 mg daily taken at least 1 hr before or 2 hr after food; Pancreatic cancer—100 mg daily taken at least 1 hr before or 2 hr after food.


Tablets: 25 mg, 100 mg, 150 mg

Nursing implications

Nursing assessment

  • Assess respiratory status prior to and periodically during therapy. If dyspnea, cough, or fever occur, discontinue erlotinib, assess for interstitial lung disease, and institute treatment as needed.
  • Assess for diarrhea. Usually responds to loperamide but may require dose reduction or discontinuation of therapy if patient becomes dehydrated.
  • Assess skin throughout therapy. If bullous, blistering, and exfoliative skin conditions, including Stevens-Johnson syndrome/toxic epidermal necrolysis, occur, interrupt or discontinue treatment. Skin rash may require treatment with corticosteroids or anti-infectives with anti-inflammatory properties; acne treatments may aggravate dry skin and erythema.
  • Assess eyes periodically during therapy. If acute or worsening eye disorders or pain occur, interrupt or discontinue therapy.
  • Assess for GI pain. Patients receiving concomitant antiangiogenic agents, corticosteroids, NSAIDs, and/or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease, are at increased risk for GI perforation. Permanently discontinue erlotinib in patients who develop gastrointestinal perforation.
  • Lab Test Considerations: Monitor liver function tests (AST, ALT, bilirubin, alkaline phosphatase) periodically during therapy. Dose reduction or discontinuation of therapy should be considered if severe changes in liver function (total bilirubin ≥3 times upper limit of normal and/or transaminases ≥5 times upper limit of normal) occur.
    • Monitor renal function and electrolytes in patients at risk for dehydration. Withhold therapy if dehydration occurs.
    • Monitor INR regularly in patients taking warfarin. May cause ↑ INR.

Potential Nursing Diagnoses

Ineffective breathing pattern (Side Effects)


  • Oral: Administer at least 1 hr before or 2 hr after food.

Patient/Family Teaching

  • Instruct patient to take erlotinib as directed.
  • Advise patient to notify health care professional if severe or persistent diarrhea, nausea, anorexia, vomiting, onset or worsening of skin rash, unexplained dyspnea or cough, or eye irritation occur.
  • Advise patient to wear sunscreen and protective clothing to decrease skin reactions.
  • Caution patient to use highly effective contraceptive during and for at least 2 wk after completion of therapy. Advise female patients to notify health care professional if pregnancy is planned or suspected or if breast feeding.
  • Instruct patient to discontinue smoking during therapy; smoking decreases blood levels of erlotinib.

Evaluation/Desired Outcomes

  • Decrease in spread of non–small-cell lung or pancreatic cancer with increased survival.


A trademark for the drug erlotinib hydrochloride.


a trademark for erlotinib.

Patient discussion about Tarceva

Q. Does anyone know anything about the drug Tarceva (from Genentech)?

A. Thanks for the info. Very helpful.

More discussions about Tarceva
Mentioned in ?
References in periodicals archive ?
This means the pharmacy at Salmaniya Medical Complex (SMC) is the only body that can dispense Tarceva, a chemotherapy drug targeting lung and pancreatic cancer.
Roche announced today that the European Commission has approved the use of Avastin (bevacizumab) in combination with Tarceva (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations.
CareMed Pharmaceutical Services has been selected to supply oncology drug Tarceva (Erlotinib).
Watchdog NICE on Thursday said that it is recommending Roche's lung cancer pill Tarceva in patients with a certain type of the disease.
Global Banking News-July 25, 2011--Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer(C)2011 ENPublishing - http://www.
M2 EQUITYBITES-January 28, 2011-Genentech and OSI Pharmaceuticals announce early meeting of primary endpoint in Tarceva Phase III EURTRAC study(C)2011 M2 COMMUNICATIONS http://www.
This open-label trial will test belinostat in combination with Tarceva in patients with previously treated NSCLC.
Patients were too ill to receive chemotherapy and were given Tarceva as a first-line treatment.
Early results from a clinical trial suggest the drug Tarceva, which is also used to treat pancreatic cancer, extends life and is most effective in women.
s (Melville NY) cancer drug Tarceva extended the survival of patients with advanced non-small cell lung cancer (NSCLC), when used immediately after chemotherapy, according to further results from the late-stage Saturn study.
Genentech has seen a Phase III study (ATLAS) of Tarceva (erlotinib) in combination with Avastin (bevacizumab) as a maintenance therapy following initial treatment with Avastin plus chemotherapy in advanced NSCLC (non-small cell lung cancer) meet its primary endpoint.
Roche Holding and Genentech said on Monday a study into the benefits of combining their Tarceva and Avastin drugs for lung cancer patients did not show an increase in overall survival.